FRANKLIN, Tenn.--(BUSINESS WIRE)--June 7, 2006--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI - News) announced today that it has received approval from Health Canada for the Canadian distribution and commercialization of its lead product, GEM 21S® for the treatment of periodontally-related bone defects and gingival recession. GEM 21S is a completely synthetic grafting system for bone and periodontal regeneration and is composed of a purified recombinant growth factor, recombinant human platelet derived growth factor (rhPDGF-BB), and a synthetic calcium phosphate matrix, beta-tricalcium phosphate (Beta-TCP). This approval follows the November 2005 milestone in which the U.S. Food and Drug Administration (FDA) approved the use of GEM 21S in the United States for similar indications making it the first totally synthetic product combining a purified recombinant growth factor with a synthetic bone matrix to be approved by the FDA for human application.
